M
MacroGenics
Developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases
At a glance
- Founded
- 2000
- Headquarters
- Rockville, United States
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning MacroGenics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- AEAlexandria Equities
InterWest Partners- SVStartech Early Ventures
OrbiMed- MBMPM BioImpact
Series B and later8 investors entered at this stage
- RURockefeller University
- IBInstitute for Systems Biology
- MVMithra Ventures
TPG- VWVentures West
- APAlta Partners
- RPRed Abbey Venture Partners
- EVETP Ventures
Source: Dealroom Talent Intelligence.
Alumni founders
Former MacroGenics employees who went on to found companies, sorted by Dealroom signal score.
NENextCureEst. 2015
Eric RisserIreland
IDIntegrated DiagnosticsEst. 2005
Leroy HoodUnited States
Paul MooreUnited States
VIVirobayEst. 2006
Heather PrestonUnited StatesGlobal footprint
team presence
across markets
Patents
69 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about MacroGenics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MacroGenics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.